Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

Ormeci, Aslı; Emrence, Zeliha; Baran, B.; Gokturk, S.; Soyer, O.; Evirgen, S.; Akyuz, Filiz; Karaca, C.; Besisik, Selman; Kaymakoglu, Sabahattin; Ustek, D.; Demir, K.

Effect of cytochrome P450 2C19 polymorphisms on the Helicobacter pylori eradication rate following two-week triple therapy with pantoprazole or rabeprazole

Atıf İçin Kopyala

Ormeci A., Emrence Z., Baran B., Gokturk S., Soyer O. M., Evirgen S., ...Daha Fazla

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, cilt.20, sa.5, ss.879-885, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 20 Sayı: 5
Basım Tarihi: 2016
Dergi Adı: EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.879-885
Anahtar Kelimeler: Helicobacter pylori, CYP2C19, Polymorphism, Pantoprazole, Rabeprazole, PROTON PUMP INHIBITORS, CYP2C19 POLYMORPHISM, OMEPRAZOLE METABOLISM, GENETIC POLYMORPHISMS, S-MEPHENYTOIN, CLARITHROMYCIN, LANSOPRAZOLE, AMOXICILLIN, RESISTANCE, INFECTION
İstanbul Üniversitesi Adresli: Evet

Özet

OBJECTIVE: Cytochrome P450 2C19 (CYP2C19) polymorphisms play an important role in the metabolism of proton pump inhibitors. Rabeprazole is primarily metabolized via non-enzymatic pathways. In this study, we determined whether rabeprazole- and pantoprazole-based eradication treatments were influenced by CYP2C19 polymorphisms.